Reports indicate that patients with non-small cell lung cancer (NSCLC) exhibiting FGFR1 gene amplification and FGFR1 protein overexpression demonstrate higher sensitivity to M6123 [83]. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.